Zandona, Antonio
Maraković, Nikola
Mišetić, Petra
Madunić, Josip
Miš, Katarina
Padovan, Jasna
Pirkmajer, Sergej
Katalinić, Maja http://orcid.org/0000-0001-7043-4291
Funding for this research was provided by:
Hrvatska Zaklada za Znanost (HrZZ-UIP-2017-05-7260)
Javna Agencija za Raziskovalno Dejavnost RS (P3-0043, J7-8276)
Ministry of Science and Technology, Croatia (Croatian-Slovenian Bilateral grant 2020-2021)
Article History
Received: 14 April 2021
Accepted: 15 June 2021
First Online: 26 June 2021
Declarations
:
: The authors have no relevant financial or non-financial interests to disclose. The authors have no conflicts of interest to declare that are relevant to the content of this article.
: All studies on the primary human skeletal muscle cells reported here were conducted at the Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. The use of human skeletal muscle cells (HSMC) was approved by the Republic of Slovenia Medical Ethics Committee (#71/05/12 and #0120-698/2017/4). The manuscript does not contain clinical studies or patient data.
: All of the authors have approved the contents of this paper and have agreed to the submission policies.